Melanotan I (afamelanotide) is a synthetic 13-amino acid analogue of alpha-melanocyte-stimulating hormone (ฮฑ-MSH) with high affinity for MC1R. It is the most clinically advanced melanocortin peptide, approved in Europe and the United States as Scenesseยฎ (Clinuvel Pharmaceuticals) for the prevention of phototoxic reactions in erythropoietic protoporphyria (EPP). Below is a curated selection of peer-reviewed studies investigating its properties.
2022
MC1R Activation by Afamelanotide Upregulates Nucleotide Excision Repair and Antioxidant Pathways
Journal of Investigative Dermatology
This study by Guida and colleagues documented that MC1R activation by afamelanotide upregulates nucleotide excision repair enzymes alongside melanin synthesis, suggesting that Melanotan I’s photoprotective effects extend beyond pigmentation to include direct DNA repair enhancement โ providing mechanistic depth to its UV protection research applications.
View Paper โ2021
Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo: A Randomized Multicentre Trial
PMC / JAMA Dermatology
This randomised controlled trial evaluated the combination of afamelanotide and narrowband UV-B phototherapy in vitiligo patients. The combination produced significantly greater repigmentation than UV-B alone, with faster onset and more extensive skin coverage, demonstrating Melanotan I’s capacity to potentiate melanocyte activity in depigmentation conditions.
View Paper โ2020
Three-Year Observational Study: Afamelanotide Increases Phototoxic Burn Tolerance and Quality of Life in EPP
Photodermatology, Photoimmunology & Photomedicine
This three-year observational study in erythropoietic protoporphyria patients found that afamelanotide consistently increased the time patients could spend in direct sunlight without phototoxic pain. Quality of life scores improved significantly across the observation period, supporting the sustained efficacy of Melanotan I in photoprotection research.
View Paper โ2016
Afamelanotide for Erythropoietic Protoporphyria: A Phase 3 Randomised Controlled Trial
PMC / JAMA
The pivotal Phase 3 trial that led to regulatory approval of afamelanotide. Patients receiving afamelanotide spent a median of 64 hours in direct sunlight without pain over 180 days, compared to 41 hours for placebo. The compound was well tolerated, establishing the clinical evidence base for Melanotan I as a photoprotective agent.
View Paper โ2015
Afamelanotide Reduces UV Radiation Erythema Response in Healthy Volunteers
British Journal of Dermatology
This controlled human study demonstrated that afamelanotide significantly reduced the UV radiation erythema dose-response in healthy subjects shortly after administration, with evidence for both melanogenic and non-melanogenic photoprotective mechanisms. The findings suggest Melanotan I’s protective properties are partly independent of pigmentation induction.
View Paper โ2023
MC1R Signalling Cascade: From Receptor Activation to Eumelanin Synthesis
PMC / International Journal of Molecular Sciences
This pharmacology review details the complete MC1R signalling pathway activated by afamelanotide โ from receptor binding through adenylyl cyclase activation, cAMP elevation, and MITF transcription factor upregulation, to tyrosinase-driven eumelanin synthesis. It provides comprehensive mechanistic context for Melanotan I’s pigmentation and photoprotective research applications.
View Paper โ